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Summary
Double-strand DNA breaks (DSB) induce chromosomal translocations and gene amplification in cell culture, but mechanisms
by which DSB cause genomic instability in vivo are poorly understood. We show that RAG-1/2-induced DSB cause IgH/
c-Myc translocations in leukemic pro-B cells from p53/Prkdc-deficient mice. Strikingly, these translocations were complex,
clonally heterogeneous and amplified. We observed reiterated IgH/c-Myc fusions on dicentric chromosomes, suggesting
that amplification occurred by repeated cycles of bridge, breakage and fusion. Leukemogenesis was not mitigated in
RAG-2/p53/Prkdc-deficient mice, but leukemic pro-B cells lacked IgH/c-Myc translocations. Thus, global genomic instability
conferred by p53/Prkdc disruption efficiently transforms pro-B cells lacking RAG-1/2-induced DSB. Unexpectedly, RAG-2/
p53/Prkdc-deficient mice also developed leptomeningeal leukemia, providing a novel spontaneous model for this frequent
complication of human lymphoblastic malignancies.
Introduction Pinho, 2002). The formation of end-to-end chromosomal fusions
(Chin et al., 1999) and gene amplification in vitro (Livingstone
Human malignancies frequently display evidence of genomic et al., 1992; Yin et al., 1992) can be suppressed by the p53-
instability, as revealed by chromosomal translocations, amplifi- dependent DNA damage response pathway, presumably by
preventing cells from replicating chromosome with dysfunc-cations, deletions, and aneuploidy (Mitelman et al., 1997; Len-
gauer et al., 1998). These genetic alterations can induce ectopic tional telomeres and DNA double-strand breaks (DSB) (Paulson
et al., 1998). Experimental induction of DSB (Pipiras et al., 1998;expression of protooncogenes or disrupt expression of tumor
suppressor genes to disregulate cell growth and survival during Richardson and Jasin, 2000), chromosomal fragile sites (Windle
et al., 1991; Coquelle et al., 1997; Hellman et al., 2002), andinitiation or progression of tumorigenesis (Marx, 2002). Gene
amplification is a common means by which tumor cells acquire defects in DSB repair by nonhomologous end-joining (NHEJ)
(Karanjawala et al., 1999; Difilippantonio et al., 2000; Fergusonresistance to chemotherapeutic agents (Schimke et al., 1978;
Gorre et al., 2001). An important mechanism of gene amplifica- et al., 2000) can also trigger translocations and gene amplifica-
tion in cultured cells. Mice with defects in NHEJ are highlytion is the breakage-fusion-bridge (BFB) cycle, in which critical
shortening or defective capping of telomeres triggers sister tumor-prone (Ferguson and Alt, 2001; Sharpless et al., 2001),
demonstrating that unrepaired DSB can be tumorigenic. How-chromatid or end-to-end chromosomal fusions. The resulting
dicentric chromosomes are unstable because they form ana- ever, mechanisms by which DSB induce genomic instability and
gene amplification in vivo are poorly understood.phase bridges that are broken during mitosis (Maser and De-
S I G N I F I C A N C E
Genomic instability is a hallmark of human malignancies, and is manifested in tumor cells by the presence of numerous chromosomal
translocations, amplifications, deletions, and aneuploidy. However, mechanisms that cause genomic instability in vivo are poorly
understood. We show that in mice with disrupted DNA damage surveillance and DSB repair, physiologically introduced DSB induce
chromosomal translocations and gene amplification through repeated bridge-breakage-fusion cycles in vivo. In addition, we show
that the pattern of genomic instability influences the clinical behavior of leukemic pro-B cells, providing a new animal model to
elucidate molecular mechanisms by which leukemic lymphoblasts invade and grow within the CNS.
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The developmentally regulated process of V(D)J recombina- p53/Prkdcscid/scid mice (Vanasse et al., 1999b). Moreover,
lymphoid oncogenesis was absolutely dependent on RAG-1/2tion requires the introduction of site-specific DNA double-strand
breaks in lymphocyte progenitors, and provides a useful model function in a small cohort of p53/XRCC4/ mice (Zhu et al.,
2002), but was RAG-1/2-independent in small cohorts ofto study general mechanisms by which improper surveillance
and repair of DSB might cause genomic instability and oncogen- p53/KU80/ or p53/Prkdcscid/scid mice (Vanasse et al.,
1999b; Difilippantonio et al., 2002). Thus, it remains unclearesis in vivo. V(D)J recombination is used to generate clonally
unique and highly diverse variable (V) region genes for antigen to what extent RAG-1/2-mediated DSB versus global genomic
instability contribute to lymphoid oncogenesis in mice with com-recognition by immunoglobulins (Ig) and T cell receptors (TCR)
(Bassing et al., 2002). It is initiated when the RAG-1/2 lympho- bined p53/NHEJ deficiencies.
In contrast to a previous report (Vanasse et al., 1999b), wecyte-specific endonuclease introduces DSB at recombination
signal sequences adjacent to V, D, and J gene segments (Fug- show here that leukemic pro-B cells from p53/Prkdcscid/scid
mice harbor recurrent IgH/c-Myc translocations. Strikingly,mann et al., 2000), generating signal end and coding end DSB
intermediates that are then repaired by NHEJ. NHEJ proteins these translocations were typically complex (involving other
chromosomes), clonally heterogeneous, and amplified, and wewith critical functions in V(D)J recombination also function ubiq-
uitously in DSB repair and include the DNA-dependent protein present evidence that they participate in BFB cycles. To deter-
mine if RAG-1/2-mediated DSB are essential to induce genomickinase (DNA-PK or Prkdc), KU70, KU80, XRCC4, DNA ligase
IV (LIG4), and Artemis (Bassing et al., 2002). While these NHEJ instability and oncogenic transformation of p53/Prkdc-deficient
lymphoid progenitors, we bred RAG-2/p53/Prkdc-deficientproteins function in concert during V(D)J recombination, KU70,
KU80, XRCC4, and LIG4 also regulate telomere function, repli- mice. We show that while RAG-1/2-mediated DSB are essential
for generating IgH/c-Myc translocations in p53/Prkdcscid/scidcative senescence, cell growth, and embryonic neurogenesis
(Bassing et al., 2002). pro-B cells, the global genomic instability conferred by loss of
p53 and DNA-PK efficiently transforms pro-B cells that lackAlthough V(D)J recombination generates valuable somatic
diversification of the germline repertoire of V genes, it may also V(D)J recombinase activity. Unexpectedly, RAG-2/p53/Prkdc-
deficient leukemias showed a unique capacity for disseminationcompromise genomic stability in lymphocyte precursors. In-
deed, many human lymphoid tumors harbor recurrent chromo- to the central nervous system (CNS), causing leptomeningeal
leukemia, an important clinical complication of human lympho-somal translocations between antigen receptor loci and pro-
tooncogenes (Look, 1997; Faderl et al., 1998; Kuppers and blastic malignancies. Collectively, our data demonstrate that
physiologically introduced DSB can promote chromosomalDalla-Favera, 2001) that are thought to arise by illegitimate re-
joining of V(D)J coding ends to DSB on other chromosomes translocations and gene amplification by repeated BFB cycles
in vivo, and we present a novel animal model that provides a(Vanasse et al., 1999a; Vaandrager et al., 2000). V(D)J coding
ends accumulate in NHEJ-deficient lymphocyte precursors unique opportunity to elucidate the molecular mechanisms by
which leukemic lymphoblasts invade and grow within the CNS.(Roth et al., 1992), and inefficient repair of these DSB intermedi-
ates impairs the generation of functional antigen receptor genes,
arresting lymphocyte development at the pro-B and pro-T Results
stages. We have previously shown that the abnormal accumula-
tion of RAG-1/2-mediated DSB in thymocytes from DNA-PK- Recurrent translocations involving chromosomes 12
and 15 in p53/Prkdcscid/scid pro-B cell leukemiasdeficient (Prkdcscid/scid) mice induces the p53-dependent DNA
damage checkpoint (Guidos et al., 1996). Thus, although RAG- We previously reported that p53/Prkdcscid/scid mice develop a
rapidly lethal pro-B cell leukemia that closely resembles acute1/2-induced DSB are restricted to lymphocyte progenitors, they
can elicit DNA damage surveillance mechanisms thought to be lymphoblastic leukemia, and that these leukemic pro-B cells
display significant levels of aneuploidy (Guidos et al., 1996). Toimportant in many cell types. This surveillance is particularly
important when lymphoid progenitors have defective NHEJ, gain insights into mechanisms leading to pro-B cell transforma-
tion in this model, we performed spectral karyotype analysissince mice lacking both p53 and various NHEJ components
rapidly develop lethal pro-B cell leukemia and/or thymic (imma- (SKY) to see if they displayed recurrent cytogenetic abnormali-
ties. We observed a high level of chromosomal instability in allture T cell) lymphoma (Guidos et al., 1996; Nacht et al., 1996;
Difilippantonio et al., 2000; Frank et al., 2000; Gao et al., 2000; p53/Prkdcscid/scid leukemias, as expected from the combined
disruption of NHEJ and p53. Clonal and nonclonal abnormalitiesLim et al., 2000).
Leukemic pro-B cells from p53/NHEJ-deficient mice display were seen, and included whole chromosome losses or gains,
segmental multiplications, dicentric chromosomes, evidence ofmany cytogenetic aberrations, such as aneuploidy, chromo-
somal translocations, and amplification (Guidos et al., 1996; gene amplification in homogeneously staining regions, nonre-
ciprocal translocations, and inversions (Table 1). Among theVanasse et al., 1999b; Difilippantonio et al., 2000), demonstra-
ting that the combined loss of p53 and NHEJ causes genomic clonal abnormalities, translocations involving either chromo-
somes 12 and 15 {t(12;15)} or 12 and 16 {t(12;16)} (Table 1 andinstability which neoplastically transforms B cell progenitors very
efficiently. Recurrent translocations involving the immunoglobu- Figure 1A) were recurrent in all leukemias. Cytogenetic analyses
of the t(12;15) breakpoints were consistent with involvement oflin heavy chain (IgH) locus on chromosome 12 and c-Myc on
chromosome 15 occur in leukemic B cells from p53/KU80/, IgH at 12F1 and c-Myc at 15D3 (Table 1). We therefore per-
formed dual color fluorescent in situ hybridization analysesp53/LIG4/, and p53/XRCC4/ mice (Difilippantonio et
al., 2000; Gao et al., 2000), suggesting that RAG-1/2-mediated (FISH) with BAC probes containing the IgC/JH and c-Myc loci.
Importantly, we observed colocalization of the IgH and c-MycDSB contribute to genomic instability and leukemogenesis in
these models. However, these potentially oncogenic trans- signals in metaphases from 5/5 leukemias harboring a t(12;15).
Thus, like the endemic form of Burkitt’s lymphoma in humanslocations were not observed in leukemic pro-B cells from
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sequential SKY/FISH to identify the chromosomes containingTable 1. Clonal chromosomal abnormalities in p53/Prkdcscid/scid pro-B cell
the IgH/c-Myc fusions, we found that in 3/5 leukemias (Type I),leukemias
the IgH/c-Myc fusions resided on a der(15) rather than on aLeukemia Structural Numerical
der(12) chromosome in most metaphases (Figure 1C and Table
528 der(11;14)(A1;A1) 6,11, 16 2). Thus, the t(12;15) were reciprocal translocations in these
der(12)t(12;16)(F1;B1)
leukemias. We did observe the IgH/c-Myc fusion onder(12)t(6;12)(C1;D1)
der(12)t(12;15) chromosomes in 2 leukemias (type II), and these544 der(2;15)(A1;A1)
der(3)t(3;15;3)(H4;?;F2) translocations appeared to be nonreciprocal (Table 2). To define
der(12)t(12;15)(F1;D3) the IgH regions relocated to the der(15)t(12;15), we compared
der(15)dupinv(15)(?A1F2)t(15;16)(?A1;B1) FISH signals using BAC probes containing the IgC gene andder(15)dupinv(15)(A1F2)t(3;15)(F2;A1)
sequences centromeric to it, and another containing the telomeric556 der(12)t(12;16)(F1;B1) Y, 6 , 16
584 dup(12)(E;F2) 3 VH genes. While these two probes colocalized on the nonre-
der(12)t(12;13)(F1;B) arranged chromosome 12 in pro-B cell leukemias (Figure 1C) and
der(12)t(12;15)(F1;D3) in normal cells (not shown), the telomeric VH gene cluster was
qdp(15)(B1 D3)
lost from the both the der(15) and der(12) chromosomes (Figurehsr(16)(C)
1C, right). Moreover, sequences hybridizing to the IgC BAC596 der(1;3)(A1;A1) 3
der(12)t(12;15)(F1;D3) were amplified on the der(15)t(12;15). These data suggested
dup(15)(**) that the process of IgH/c-Myc translocation began with RAG-
599 der(12)t(12;15)(F1;D3) 3, 6 1/2-mediated cleavage of VDJH gene segments and loss of thet(14;15)(E3;E)
subtelomeric VH gene cluster.601 der(3)t(3;3)(A1;D)
der(12)t(12;15)(F1;D3) The clonal instability of IgH and the IgH/c-Myc fusions is
further illustrated in Figure 2. For example, sequential SKY/FISHTen metaphases were analyzed by SKY for each DM leukemia. Karyotype
analyses of leukemia 544 showed that some der(15) chromo-descriptions are based on ISCN 1995 guidelines and standard mouse chro-
mosome nomenclature. Multiple nonclonal changes were also observed somes had IgH/c-Myc fusions at the extreme telomeric end,
in all leukemias, reflecting ongoing genomic instability in these cells (data whereas in others, IgH/c-Myc fusions resided at the junctions
not shown). of the der(15) with a third chromosome (eg., t[3;15] or t[15;16]?, chromosome band not identified.
in Figure 2A). Similarly complex translocations were observed**, different levels of amplification in different metaphases.
in all other leukemias (Table 2 and data not shown). Interestingly,
we also found the IgH/c-Myc fusions on “third party” chromo-
somes, such as 16 (Figure 2A), 2 (Figure 2B), and 3 (data not
shown). Moreover, amplified IgH sequences without c-Myc were
(Faderl et al., 1998), the pro-B cell leukemias that arose in seen on chromosome 12 and on a third party chromosome
p53/Prkdcscid/scid mice are characterized by recurrent translo- (Figure 2B). Importantly, these observations suggest that RAG-
cations that juxtapose IgH and c-Myc. 1/2-mediated loss of telomeric VH can destabilize the IgH locus
on chromosome 12 independently of translocation with c-Myc.
IgH/c-Myc translocations are complex and amplified Finally, we observed reiterated or amplified IgH/c-Myc fusions
Surprisingly, however, we observed dramatic clonal heteroge- on dicentric chromosomes, as well as ladder-like interspersions
neity in IgH/c-Myc fusion patterns among different metaphases of chromosome 15 with other chromosomes by SKY (Figure
within each leukemia (Figure 1B). The IgH/c-Myc fusions were 2C). Collectively, these data strongly suggest that repeated BFB
present in 1–5 copies and were distributed between 1–3 individ- cycles generate clonally unstable and complex IgH transloca-
ual chromosomes in each metaphase. In addition, the IgH/ tions in p53/Prkdcscid/scid pro-B cell leukemias.
c-Myc fusions were frequently amplified, often to different de-
grees on the same chromosome. In several leukemias (528, Effect of RAG-2 deficiency on lymphoid tumorigenesis
584, and 599), we also observed metaphases with striking ampli- in p53/Prkdcscid/scid mice
fication of the IgH locus on a nonrearranged chromosome 12 The above cytogenetic observations provided strong circum-
(Figure 1B and data not shown). These observations suggested stantial evidence that RAG-1/2-mediated DSB could initiate the
that both the IgH locus and the IgH/c-Myc fusions were geno- process of IgH/c-Myc translocations in p53/Prkdcscid/scid pro-B
mically unstable in p53/Prkdcscid/scid leukemias, due to ongoing cell leukemias. However, given the global genomic instability in
rearrangement and amplification. these leukemias, we could not rule out the possibility that the
The IgH locus on chromosome 12 is oriented with the IgCH IgH/c-Myc translocations were generated by RAG-1/2-indepen-
region cluster located on the centromeric side of the V(D)JH dent mechanisms but were strongly selected for during leuke-
gene cluster (D’Eustachio and Riblet, 1999). The most distal VH mogenesis. To test the requirement for RAG-1/2-mediated DSB
genes are found in the subtelomeric region of chromosome 12. for leukemogenesis in this model, we generated RAG-
By analogy with the human t(8;14) translocations that fuse IgH/ 2/p53/Prkdcscid/scid triple mutant (TM) mice and compared
c-Myc in the endemic form of Burkitt’s lymphoma (Faderl et al., their morbidity due to lymphoblastic leukemia to RAG-
1998), we expected that c-Myc would be relocated into the D/J 2/p53/Prkdcscid/scid or RAG-2/p53/Prkdcscid/scid double
region of IgH on murine chromosome 12, bringing c-Myc under mutant (DM) mice. Two breeding schemes were used to mini-
transcriptional control of the intronic or 3 IgH enhancers (D’Eus- mize modifier gene effects: RAG-2/Prkdcscid/scid mice segregat-
tachio and Riblet, 1999). However, a previous study did not find ing p53 alleles, and p53/Prkdcscid/scid mice segregating RAG-2
IgH/c-Myc fusions on the derivative chromosome 12 {der(12)} alleles (Figure 3A and Experimental Procedures). All DM mice
developed leukemia with a median latency of 9 weeks, as ex-in p53/Prkdcscid/scid leukemias (Vanasse et al., 1999b). Using
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Figure 1. Chromosomal translocations involving IgH and c-Myc in DM leukemias
A: SKY and inverted DAPI images showing normal and derivative chromosomes 12, 15, and 16 from the indicated DM leukemias (see Table 1 for detailed
karyotype description).
B: Amplification and mobilization of IgH/c-Myc fusions in DM leukemias 544 and 584. The BAC probes used for FISH contained IgC (MBAC 20B20, green)
and c-Myc (MBAC 270G24, red). Each leukemia showed clonal heterogeneity and amplification of IgH/c-Myc fusions (yellow). Each panel shows a
nonrearranged chromosome 12 with IgH only (green) or chromosome 15 with c-Myc (red) only on the right.
C: Chromosomal location and structure of IgH/c-Myc fusions in DM leukemia 544. Sequential SKY (left) and dual color FISH analysis revealed colocalization
of IgC (MBAC 20B20, green) and c-Myc (MBAC 270G24, red) on a der(15)t(3;15) (middle) and loss of subtelomeric VH genes (BAC CT7-224M14, green)
from the der(12) and movement of the 3 IgC region (BAC CT7-199M11, red) to the der(15)t(3;15) (right). A similar pattern was observed with DM leukemia
601 (not shown).
pected in accordance with our previous study of RAG- 2001), and document here that heterozygosity for p53 provides
significant protection, as only 3% of RAG-2/p53/Prkdcscid/scid2/p53/Prkdcscid/scid mice (Guidos et al., 1996). We have pre-
viously shown that RAG-2/p53/Prkdcscid/scid mice do not de- developed leukemia (median latency, 27.5 weeks). Strikingly,
RAG-2 genotype had no effect on the survival of p53/velop lymphoid malignancies by 6 months of age (Williams et al.,
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Table 2. Location of IgH, c-Myc, and IgH/c-Myc fusions in p53/Prkdcscid/scid pro-B cell leukemias
Type No. Freq. IgH c-Myc IgH/c-Myc No signal
I 601 10/15 12 15, der(12)t(12;15) der(15)t(12;15)
4/15 12 15 der(15)t(12;15) der(12)t(12;15)
rare 12, der(12)t(12;15) 15 2 on der(15)t(15;12;16)
1 on der(16)t(16;15;12)
I 544 8/20 12, der(12)t(12;15) 15 2 on der(15)amp(15)t(3;15)
9/20 12, der(12)t(12;15) der(2;15) 2 on der(15)amp(15)t(15;16)
3/20 12, der(12)t(12;15) 15 2 on der(15)amp(15)
rare 12, der(12)t(12;15) 15 der(15)t(15;12;15;16)*
rare 12, der(15)t(15;12;15;3) 15 der(15)t(15;12;15;3)* der(12)t(12;15)
der(15)t(16;15;16)
I 596 11/20 12, der(12)t(12;15) 15 2 on der(15)amp(15)
7/20 12, der(12)t(12;15) 15 3 on der(15)amp(15)
2/20 12, der(12)t(12;15) 15 3 on der(15)amp(15)t(15;12;…)
rare 12, der(12)t(12;15) 15 5 on dic(15;15)
II 599 8/11 12 15 der(12)t(12;15) der(14)t(14;15)
der(15)t(14;15)
3/11 12 15 der(12)t(12;15) der(15)t(15;14;15;14)
rare 12 15 der(12)t(12;15)
dic(14;15)t(14;15;14;…)*
rare 12** 15 der(12)t(12;15)
rare 12 15 2 on der(15)t(15;12;15;12…)** der(12)t(12;15)
II 584 8/20 12, dup(12)*** 15,15 none
8/20 12 15 1 on der(12)t(12;15)
2 on der(12)t(12;15)**
rare 12 15,15 der(12)t(12;1;6)***
rare 12 15,15 2
rare 12, 12, der(16)t(12;16)* 15,15 none
The chromosomal locations for IgH, c-Myc, and IgH/c-Myc fusions were determined on 11–20 metaphases from each DM leukemia by sequential SKY/FISH.
Signals showing slight (*), moderate (**), or high (***) levels of amplification are indicated. In Type I leukemias, the IgH/c-Myc fusions are predominantly on
the der(15) chromosome, whereas in Type II leukemias they are predominantly on the der(12) chromosome.
Prkdcscid/scid mice, as TM and DM mice became moribund with normal neurological exam. CNS symptoms were rarely observed
identical kinetics (Figure 3A). Flow cytometric evaluation of in DM (4%), RAG-2/p53/Prkdcscid/scid (3%), or RAG-
lymphoid tissues demonstrated that 40/42 TM mice and 39/40 2/p53/Prkdcscid/scid (5%) mice, and were not seen in RAG-
DM mice examined had disseminated pro-B cell leukemia, 2/p53/Prkdcscid/scid mice. Normal lateral ventricular and
whereas 2/42 TM and 1/40 DM mice had pre-T cell lymphoblas- choroid plexus architecture was seen in neurologically asymp-
tic leukemia/lymphoma (pre-TLL, previously called thymic lym- tomatic RAG-2/p53/Prkdcscid/scid mice (Figure 4Aii). How-
phoma) (Morse et al., 2002). Finally, 3/42 TM and 2/40 DM mice ever, all affected TM mice showed dilation of cerebral ventricles,
had both pro-B and pre-TLL. Leukemia incidence and latency signifying communicating hydrocephalus (Figure 4Aiii), account-
in TM mice generated by the two breeding strategies were ing for the domed head appearance. The cortical surface of the
indistinguishable (data not shown). Leukemic cells in the bone brain from asymptomatic RAG-2/p53/Prkdcscid/scid mice was
marrow of each strain displayed similar pro-B cell phenotypes normal (Figure 4Aiv). 11 of 23 (48%) DM mice had thin patchy
(B220CD19CD43IgM, data not shown). Both TM and DM infiltrates (2 cells thick) of leukemic cells in the subarachnoid
leukemias disseminated to lymph node, spleen, and thymus, (leptomeningeal) space (Figure 4Av), but they did not display
but in many TM mice this was evident only by flow cytometric neurological impairment. In contrast, symptomatic TM mice
examination of these tissues. TM mice rarely displayed the gross
showed a prominent infiltration of mononuclear cells animals
lymphadenopathy and thymic enlargement that was typical for
(10 cells thick) within the leptomeninges (Figures 4Avi andDM mice. We conclude that loss of RAG-1/2 function did not
4Avii), but infiltration of the brain parenchyma was never ob-alter the incidence or latency of lymphoblastic leukemia in
served. This leukemic infiltrate was absent in TM mice lackingp53/Prkdcscid/scid mice.
signs of CNS impairment. Cells infiltrating the leptomeninges
of TM mice expressed B220 and CD19, identifying them asLeptomeningeal dissemination of leukemic pro-B cells
leukemic B-lineage cells (Figure 4Aviii and data not shown). Noimpairs CNS function in TM mice
significant cellular infiltrate was seen in the spinal cord of TMSurprisingly, however, RAG-2 genotype exerted a profound ef-
mice, ruling out malignant compression as the cause of hindfect on the clinical course of leukemia in p53/Prkdcscid/scid mice.
limb paresis (data not shown). We conclude that the neurologicalWe observed a high incidence (73%) of neurological impairment
symptoms seen in TM mice resulted from hydrocephalusconcomitant with morbidity from systemic leukemia in TM mice
caused by dissemination of leukemic pro-B cells to the lepto-(Figure 3B). Neurologic findings included a domed head (Fig-
meningeal space. Importantly, these pathological findingsure 4Ai), ataxic gait, and/or hind limb paresis. Progression of
closely resemble CNS (leptomeningeal) leukemia, a frequentCNS disease was very rapid, and TM animals commonly be-
came paralyzed and unable to drink or feed 24 hr after a and morbid complication of acute lymphoblastic leukemia and
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Figure 2. Clonal heterogeneity and amplification of IgH and IgH/c-Myc fusions
SKY (left) and FISH (right) images of chromosomes containing IgC (MBAC 20B20, green), c-Myc (MBAC 270G24, red) or fused (yellow) signals. Each row
shows chromosomes from individual metaphases of DM 544 (A) and DM 584 (B). In both leukemias, the IgH/c-Myc fusions were found on several different
chromosomes, some of which captured the telomeric end of a third chromosome.
B: In DM 584, IgH was amplified on a dup(12) or was inserted into a der(16)t(12;16).
C: Dicentric chromosomes and complex translocations harboring IgH/c-Myc fusions indicative of ongoing BFB cycles. Left: dicentric (15;15) from DM 596.
Middle: dicentric (14;15;14;15;14;15) from DM 599. Right: der(15)amp(15)t(15;12;15;12;15) from DM 596.
non-Hodgkin’s lymphoma (Price, 1979; Pui and Evans, 1998; unstable (Table 3). However, no recurrent aberrations were ob-
served among all TM leukemias, and translocations involvingSandlund et al., 2000).
We performed adoptive transfer experiments to determine chromosomes 12 and 15 were never seen. Interestingly, how-
ever, 3/5 had translocations in which one chromosomal segmentif the differential incidence of CNS leukemia in TM versus DM
mice reflects genotype-dependent properties intrinsic to the was fused with multiple different partners (Table 3 and Figure
4B), suggesting that multiple rounds of breaking and rejoiningleukemic pro-B cells. RAG-2/ hosts (sublethally irradiated)
were injected with leukemic pro-B cells isolated from lymphoid occurred at one site. For example, TM leukemia 485 contained
several derivative chromosomes 14 {der(14)} in which 14D wastissues of three TM mice with CNS impairment, or from two
DM mice with no neurological involvement. Recipients of TM fused with portions of chromosome 3, 4, 12, or 19 (Figure 4B,
top). Several observations suggest that repeated BFB cyclesleukemias rapidly developed neurological symptoms (mean on-
set of symptoms 3 weeks), and flow cytometric analysis of their could account for these chromosomal anomalies in TM leuke-
mias. First, we observed end-to-end fusions of the multiplylymph nodes, spleen, thymus, and bone marrow revealed heavy
infiltration of leukemic pro-B cells (data not shown). In addition, translocated chromosome with other chromosomes, creating
dicentrics (dic[4;17] in TM 560 and dic[2;14] in TM 485, Figurehistological examination of TM recipient brains revealed CNS
leukemia (Figure 4Aix). In contrast, recipients of DM leukemias 4B). Second, we observed broken versions (del[14D] in TM 485
and del[2G] in TM 518) of the multiply translocated chromo-rapidly succumbed to systemic leukemia without signs of CNS
involvement. Thus, leptomeningeal dissemination reflected cell- somes. Finally, several TM leukemias had amplification of large
chromosomal segments (Table 3).intrinsic differences between TM and DM leukemic pro-B cells.
Southern blot analyses confirmed that the IgJH region re-
mained in germline configuration in TM leukemias (Figure 5A).Genomic instability in TM pro-B cell leukemias
Like the DM leukemias, all TM pro-B cell leukemias analyzed In contrast, all DM leukemias harbored IgH rearrangements and/
or loss of IgJH4 germline sequences, demonstrating deletion ofdisplayed a wide spectrum of clonal and nonclonal chromo-
somal aberrations, documenting that they were also genomically this genomic region. As expected from the cytogenetic studies,
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tion to the IgH locus. Interestingly, we also observed overex-
pression of N-Myc in 2/9 pro-B cell leukemias (Figure 5B). In
one case, this was accompanied by N-Myc amplification (data
not shown). Thus, ectopic expression of c-Myc and/or N-Myc
is a common feature of both TM and DM leukemias.
Discussion
Induction of translocations and BFB cycles by RAG-1/2
in p53/Prkdcscid/scid pro-B cells
Complex translocations with amplification have been previously
noted in solid tumors and treatment-related leukemias and lym-
phomas (Felix et al., 1998; Tanaka and Kamada, 1998; Padilla-
Nash et al., 2001), but mechanisms underlying the generation
of these chromosomal aberrations in vivo are poorly understood.
Here, we show that RAG-1/2-induced DSB can cause IgH/
c-Myc translocations in p53/Prkdcscid/scid pro-B cells that be-
come rearranged and amplified by BFB in vivo, generating com-
plex chromosomal aberrations similar to those caused by telo-
mere dysfunction (Artandi et al., 2000; Rudolph et al., 2001). Two
groups have recently reported very similar cytogenetic findings
during pro-B cell leukemogenesis in p53/Ku80/ and
p53/LIG4/ mice (Difilippantonio et al., 2002; Zhu et al.,
2002). Thus, combined disruption of p53 and any NHEJ compo-
nent promotes pro-B cell leukemogenesis by a common mecha-
nism involving RAG-1/2-induced IgH/c-Myc translocations and
their amplification by BFB. This process is initiated by RAG-1/
2-induced DSB, which cause loss of the VH gene cluster from
Figure 3. Effect of p53 and RAG-2 genotype on survival of Prkdcscid/scid mice the extreme telomeric end of chromosome 12. The presence
A: Kaplan-Meier analysis of mortality of Prkdcscid/scid (SC) mice up to 20 weeks of IgH/c-Myc fusions on either der(12) or der(15) chromosomes
of age according to RAG-2 (R2) and p53 genotype. Mice were euthanized suggests two different scenarios for resolving this broken chro-
and tissues removed for histology and flow cytometry when they showed mosome 12 (Figures 6A and 6B). In the first scenario, a sponta-
signs of morbidity (wasting, labored breathing, lymphadenopathy, domed
neous DSB centromeric to c-Myc could allow a large telomerichead, or paresis). The survival of RAG-2/p53/Prkdcscid/scid mice is shown
segment of chromosome 15 to be aberrantly joined to the bro-for comparison.
B: Frequency of CNS pathology in the indicated mouse strain. Most RAG- ken chromosome 12, generating an IgH/c-Myc fusion on a
2/p53/Prkdcscid/scid mice (73%) exhibited symptoms of neurological dis- der(12) chromosome (Type II leukemias, Table 2). This nonrecip-
ease (domed head, ataxia, and/or hind limb paresis) at the time of sacrifice.
rocal exchange would leave a broken chromosome 15 that getsNeurologic signs were observed in the other strains as follows: RAG-
lost from the cell, or undergoes BFB cycles (Figure 6A). Consis-2/p53/Prkdcscid/scid (2/49), RAG-2/p53/Prkdcscid/scid (5/192), and RAG-
2/p53/Prkdcscid/scid (2/50) mice. Control RAG-2/p53/Prkdcscid/scid mice tent with the latter notion, we observed multiple translocations
did not develop leukemia or signs of CNS pathology. involving chromosome 15 in metaphases harboring the IgH/c-Myc
fusion on a der(12) chromosome in leukemia 599 (Table 2).
In the second scenario, reciprocal translocations occur be-
tween chromosomes 12 and 15 (Type I leukemias, Table 2),
clonal heterogeneity of IgH rearrangements was evident in some generating a dicentric (12;15) harboring the IgH/c-Myc fusion,
DM leukemias: rearrangements were present in subgenomic and a der(12)t(12;15) with IgH only (Figure 6B, steps 1–3). The
quantities in DM 556 and 601, and DM 584 contained several dicentric (12;15) would likely break during anaphase, initiating
IgJH rearrangements that were amplified to different degrees. the BFB cycle and leaving the IgH/c-Myc fusion on a broken
Amplification of c-Myc sequences was also evident in some der(15) (step 4). In accordance with this notion, we observed
DM leukemias, but not in three TM leukemias examined (Figure several aberrant der(15) chromosomes that likely represent in-
5A). Based on the absence of t(12:15) translocations and IgH termediates in this iterative process. For example, we typically
rearrangements from TM leukemias, we conclude that RAG-1/2 saw IgH/c-Myc at the extreme ends of der(15) chromosomes
is absolutely required to generate the recurrent IgH/c-Myc trans- (Figure 2A), suggesting that they were broken and lacked telo-
locations seen in p53/Prkdcscid/scid leukemias. Nonetheless, the meres (Figure 6B, steps 5 and 7). In addition, we observed
global genomic instability conferred by loss of p53 and DNA- der(15) chromosomes with 1–3 copies of IgH/c-Myc inter-
PK is sufficient to rapidly transform pro-B cells in the absence spersed with segments of chromosome 15 (Figure 2A, top) or
of RAG-1/2-induced translocations. chromosome 12 (Figure 2C, right), as would be predicted by
c-Myc mRNA was markedly overexpressed in most pro-B the BFB model. Finally, we observed a dicentric (15;15) chromo-
cell DM leukemias relative to normal pro-B cells (Figure 5B), some with a ladder-like distribution of 5 IgH/c-Myc fusions (Fig-
regardless of whether the c-Myc gene was amplified. Some TM ure 2C, left), indicative of ongoing BFB cycles (Figure 6B, step
leukemias also overexpressed c-Myc, indicating that dysregula- 8a). Our data suggest that broken der(15) chromosomes can
also capture segments of third party chromosomes, resultingtion of c-Myc expression can occur independently of transloca-
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Figure 4. CNS leukemia and chromosomal insta-
bility in TM mice
A: CNS histopathology.
(i) Gross cervical lymphadenopathy and domed
head in a TM mouse with ataxia and hind limb
paresis (left) compared to an asymptomatic
RAG-2/p53/Prkdcscid/scid littermate (right).
(ii) H&E stained coronal brain section from a
RAG-2/p53/Prkdcscid/scid mouse that did not
show CNS signs demonstrating normal lateral
ventricular architecture and the choroid plexus.
(iii) H&E stained coronal brain section from a TM
mouse with hind limb paresis and ataxia showing
massive dilation of the lateral ventricle, charac-
teristic of hydrocephalus.
(iv) Cortical brain surface of a RAG-2/
p53/Prkdcscid/scid mouse without neurological
signs showing normal leptomeninges with no leu-
kemic infiltrate.
(v) A thin layer of leukemic cells is seen in the
subarachnoid space of a DM mouse that did not
have any neurological signs. This mouse, repre-
sentative of 48% (11/23) of this genotype, had
scanty subarachnoid cellular infiltrate but no
signs of neurological impairment.
(vi) Extensive leptomeningeal infiltration in the
cerebellum in a RAG-2/p53/Prkdcscid/scid
mouse with hind limb paresis and ataxia. The cells
were not observed in the brain parenchyma and
were limited to the subarachnoid space.
(vii) Higher power view of the surface of the cere-
bral hemisphere from the same mouse in (vi)
demonstrating the extensive distribution of leu-
kemia throughout the subarachnoid space.
(viii) Immunohistochemical staining with anti-
B220 confirms that the cellular infiltrate in coronal
sections from a TM brain is pro-B cell leukemia.
B220 positive cells were not seen within the brain
parenchyma.
(ix) H&E stained coronal section of a sublethally
irradiated RAG-2/ mouse 3 weeks after injec-
tion of 107 leukemic cells from a TM donor with
hind limb paresis and ataxia. In all recipients of
TM leukemic cells, the subarachnoid space was
heavily infiltrated and the mice developed CNS
signs.
B: Chromosomal instability in TM pro-B cell leuke-
mias.
(i) Translocations or deletions of chromosome
14D seen in different metaphases from leukemia
485; clockwise from top left: t(12;14), t(4;11;14), t(3;14), dic(2;14), t(14;19), and del(14). Although the TCR	 locus maps near band 14D, FISH analysis with
probes to the extreme proximal and distal regions of this 1 Mb locus revealed that the TCR	 locus was not disrupted by these rearrangements (data
not shown).
(ii) Translocations of chromosome 17E5 seen in different metaphases from leukemia 560; from the left to right: dup(17), dup(17)t(11;17), and dic(4;17).
in complex translocations. For example, the dicentric (14;15) to chromosome 16 (Figure 2B, bottom). Since the IgH locus
remained in germline configuration in TM leukemias, it is likelywe observed (Figure 2C, middle) could have been generated
by end-to-end fusion of a broken der(15) with chromosome 14 that this process was also initiated by the RAG-1/2-mediated
loss of telomeric VDJH sequences on chromosome 12, generat-(Figure 6B, step 8b). If this dicentric breaks during anaphase,
the IgH/c-Myc fusion could move to chromosome 14 (step 9). ing a broken chromosome 12 that participates in BFB cycles
(Figure 6C).Alternatively, a broken der(15) could capture the telomeric por-
tion of a third chromosome (step 8c). Indeed, we frequently
observed IgH/c-Myc fusions at the junction of the der(15) and Role of ectopic c-Myc expression and p53 deficiency
in transforming DNA-PK-deficient pro-B cellstelomeric regions of other chromosomes (Figure 2A).
Interestingly, we also observed considerable instability of Most pro-B cells from Prkdcscid/scid mice undergo apoptosis be-
cause they fail to make in-frame IgH rearrangements that allowthe IgH locus independently of translocation with chromosome
15. This was manifested by dramatic amplification of IgH se- them to express a pre-B cell receptor (Muljo and Schlissel,
2000). It seems likely that this developmental checkpoint isquences on a nonrearranged chromosome 12 (Figure 2B, top,
and Table 2), and by movement of amplified IgH sequences circumvented in p53/Prkdcscid/scid pro-B cells by the IgH/c-Myc
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Table 3. Clonal chromosomal abnormalities in TM pro-B cell leukemias
Leukemia Structural Numerical
485 der(14)t(14;*)(D;*) Y, 6, 7
513 der(2)t(2;5)(F;C1) 5, 14
518 der(2)t(2;*)(G;*) 5
del(2)(G)
der(5;6)(A1;A1)
560 dic(17;*)(E5;*) 13
dup(17)(D;E5)
605 der(3;19)(A1;A1) 3, 15
der(7;15)(A1;A1)
der(15;15)(A1;A1)
dup(16)(B4C4)
dup(17)(CE5)
Ten metaphases were analyzed by SKY for each TM leukemia, as described
for Table 1.
*, different translocation partners in each metaphase.
translocations, which cause ectopic expression of c-Myc. Our
data suggest two mechanisms for promoting c-Myc overexpres-
sion in p53/DNA-PK-deficient pro-B cell leukemias. First, a
translocation could place c-Myc under control of the intronic
or 3 IgH enhancers. This mechanism is likely operative in leuke-
mias 599 and 601, which harbor IgH/c-Myc fusions which are
only amplified in rare metaphases (Table 2 and Figure 5A). Alter-
natively or additionally, the amplification of c-Myc that occurs
during repeated BFB cycles could contribute to its overexpres-
sion in some DM leukemias.
p53 deficiency likely serves two important functions during
pro-B cell leukemogenesis in DNA-PK deficient mice. First, p53
deficiency prevents apoptosis or cell cycle arrest in response
to short telomeres (Chin et al., 1999) or unrepaired RAG-1/2-
mediated DSB (Guidos et al., 1996). This would allow pro-B
cells to replicate broken chromosomes which could undergo
sister chromatid or end-to-end chromosomal fusions to gener-
ate dicentrics that perpetuate BFB cycles. Second, ectopic ex-
pression of c-Myc triggers normal cells to undergo p53-depen-
dent apoptosis, and p53 mutations are highly selected for in B
cell lymphomas induced by transgenic overexpression of c-Myc
Figure 5. A: Southern analysis of IgH and c-Myc loci in TM and DM leukemias.(Eischen et al., 1999; Schmitt et al., 1999). Similarly, a high
A Southern blot containing the indicated samples of EcoR1-digested geno-proportion of Burkitt’s lymphomas have p53 mutations (Krug et
mic DNA was sequentially hybridized to c-Myc followed by Ig-C (top),
al., 2002). Thus, the p53-deficiency in our model obviates the IgJH4 (middle), and 
-actin (bottom) cDNA probes. SC53.3 is a RAG-
need for somatic inactivation of p53 to allow survival of c-Myc 2/p53/Prkdcscid/scid leukemic pro-B cell line (Guidos et al., 1996). Amplifi-
cation of c-Myc and IgC was seen in DM leukemia 584 and amplificationoverexpressing cells.
of c-Myc alone was seen in DM leukemia 544 when standardized to a

-actin loading control.
RAG-1/2 independent lymphoid oncogenesis B: Northern analysis of c-Myc and N-Myc expression in DM and TM leukemias.
in p53/Prkdcscid/scid mice Densitometry ratios of c-Myc to HPRT or N-Myc to HPRT are shown for each
sample. Note that normal RAG-2/ pro-B cells and DM 584 have 2.0 andWe demonstrate that RAG-1/2-deficiency did not impact the
2.5 kb N-Myc transcripts, but TM560 lacks the 2.5 kb transcript.incidence or latency of pro-B and pre-T cell leukemogenesis in
a cohort of 55 RAG-/2/p53/Prkdcscid/scid mice. In contrast,
another group reported that in a small cohort of RAG-/2-defi-
cient p53/Prkdcscid/scid mice, 8/14 developed pre-TLL (and 1
However, we have found that pro-B cell leukemia was similarlyof these also had leukemic pro-B cells in the thymus) or sar-
prevalent in p53/Prkdcscid/scid (129/Sv and ICR) and p53/coma, and the other 6 died from undocumented causes (Va-
Prkdcscid/scid (129/Sv and C.B-17) mice (C.J.W., C.J.G., andnasse et al., 1999b). Thus, RAG-1/2-deficiency altered the lin-
J.S.D., unpublished data). Moreover, the much higher preva-eage specificity of tumorigenesis and prolonged the lifespan of
lence of pro-B cell leukemia relative to pre-TLL was identicalp53/Prkdcscid/scid mice in that study. The genetic background
in our DM and TM mice. Thus, we do not believe that theof TM mice generated by Vanasse et al. was similar to ours,
presence of C.B-17 background genes in our TM mice explainsand included 129/Sv, C57BL/6, and ICR, but our genetic back-
ground also included C.B-17 (see Experimental Procedures). why we observed a high incidence of pro-B cell leukemia and
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Figure 6. Model for generation of IgH/c-Myc translocations and amplification by BFB
A: Nonreciprocal translocation of chromosomes 12 and 15 (Type II leukemias, Table 2). A spontaneous DSB on the centromeric side of c-Myc on 15 and
a second RAG-1/2-induced DSB on 12 facilitate fusion of the c-Myc-containing telomeric portion of 15 to the IgC gene cluster on 12. This process would
generate a der(12)t(12;15), leaving a “broken” 15 lacking a telomere.
B: Reciprocal translocation of chromosomes 12 and 15 (Type I leukemias, Table 2). Failure to repair RAG-1/2-induced DSB at IgH VDJ gene segments causes
loss of the telomeric segment of chromsome 12 (1). After replication of this broken chromosome (facilitated by p53 deficiency), one broken 12 chromatid
joins to a DSB telomeric of c-Myc on 15 (2), generating a dicentric (12;15) intermediate (3b). The other broken 12 chromatid joins to the telomeric segment
of 15, generating a der(12)t(12;15) with IgH but not c-Myc (3a). The unstable dicentric (12;15) breaks centromeric to IgC during anaphase, generating
a der(15) chromosome harboring the IgH/c-Myc fusion but lacking a telomere (4). The broken der(15) replicates (5) and the chromatids fuse forming a
dicentric (15;15) with 2 copies of the IgH/c-Myc fusion (6). The dicentric breaks again during anaphase (7). Data shown in Figure 2B and Table 2 suggest
3 possible fates for this broken der(15) chromosome. After it replicates, sister chromatid fusion generates another dicentric (15;15) that reenters the BFB
cycle (8a). The broken der(15) could also undergo end-to-end fusion with a different chromosome (8b). Breakage of the resulting dicentric during anaphase
could result in the IgH/c-Myc fusions moving to this third party chromosome (9). Finally, the broken der(15) could capture the telomeric portion of a third
chromosome (8c).
C: Model for IgH amplification. RAG-1/2-mediated DSB induce loss of the telomeric VDJH sequences. After replication of this broken chromosome 12 (1),
sister chromatid fusion could generate a (12;12) dicentric (2) that participates in BFB cycles leading to IgH amplification on chromosome 12 (3 and 4a).
Alternatively, the broken 12 could form a dicentric with a second chromosome (4b). If this dicentric breaks appropriately, IgH could move to this other
chromosome (5), as we observed in Figure 2B.
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low incidence of pre-TLL, whereas Vanasse et al. reported the or N-Myc by mechanisms not involving translocation to the IgH
opposite in their TM mice (Vanasse et al., 1999b). Nonetheless, locus (Figure 5). These two genes are functionally redundant in
genetic background has a well-documented effect on the inci- developing lymphocytes (Malynn et al., 2000).
dence and latency of lymphoid tumorigenesis in Prkdcscid/scid and Interestingly, we showed that RAG-1/2-deficient pro-B cell
RAG-/2/ mice. For example, pre-TLL occurs with much higher leukemias displayed many chromosomal aberrations indicative
incidence and shorter latency in NOD.Prkdcscid/scid relative to C.B- of genomic instability, but no recurrent IgH/c-Myc transloca-
17.Prkdcscid/scid mice (Custer et al., 1985; Prochazka et al., 1992). tions. Thus, RAG-1/2 function is required to generate these
Moreover, 44% of NOD.RAG-/2/ mice develop spontaneous translocations in p53/Prkdcscid/scid pro-B cell leukemias. How-
pre-TLL and pro-B cell leukemia by 10 months of age (Chiu et ever, DSB that occur spontaneously due to replication blocks,
al., 2002), whereas no lymphoid tumors have been reported in oxidative damage, or at chromosomal fragile sites likely induce
RAG-2-deficient mice on other genetic backgrounds. Thus, it chromosomal instability that is sufficient to transform TM pro-B
is possible that the latency of lymphoid tumorigenesis was
cells. Indeed, nonlymphoid cells from NHEJ-deficient and p53/
skewed by modifier genes in the small TM cohort analyzed by
NHEJ-deficient mice display striking genomic instability andVanasse et al. Finally, Vanasse et al. did not document brain
elevated frequencies of nonreciprocal translocations (Fergusonhistopathology in their TM mice, so undetected CNS leukemia
et al., 2000; Gao et al., 2000), demonstrating that spontaneouslymay have accounted for the unexplained death of nearly 50%
generated DSB are often misjoined when NHEJ is compromised.of their cohort. This unexpected complication was rapidly pro-
The telomere capping defect conferred by the DNA-PK mutationgressive and fatal in our TM mice, and often developed in the
(Bailey et al., 1999; Gilley et al., 2001; Goytisolo et al., 2001)absence of bulky extramedullary tumors.
may also promote the formation of dicentric chromosomes thatThe RAG-1/2-dependence of pro-B cell leukemogenesis has
undergo repeated BFB cycles in TM pro-B cells. Our observationalso recently been assessed in small cohorts of other p53/NHEJ-
that several TM leukemias harbor translocations in which a par-deficient mice, with discordant results. Alt’s group reported no
ticular chromosomal segment is translocated to multiple differ-lymphoid malignancies in 6 RAG-2/p53/XRCC4-deficient mice
(Zhu et al., 2002), whereas Nussenzweig and colleagues re- ent partners is consistent with these notions.
ported that 4 RAG-/2/p53/KU80-deficient mice developed pre-
TLL but not pro-B cell leukemia (Difilippantonio et al., 2002). If A novel mouse model of spontaneous CNS leukemia
verified with larger cohorts, these data, in conjunction with ours, Although RAG-1/2 function did not affect the incidence or la-
would suggest that pro-B cell leukemogenesis is completely tency of lymphoid oncogenesis in p53/Prkdc-deficient mice,
RAG-1/2-dependent in p53/XRCC4-deficient and p53/KU80- most TM mice displayed signs of acute neurological impairment
deficient mice, but completely RAG-1/2-independent in p53/
and had prominent infiltration of leukemic pro-B cells within the
Prkdc-deficient mice. This dichotomy may reflect the differential
leptomeninges. In contrast, DM mice rarely showed neurologicaleffect of these NHEJ mutations on DSB repair: V(D)J joining is
impairment or leptomeningeal dissemination of leukemic pro-Bmore severely affected by loss of XRCC4/LIG4 or KU70/KU80
cells. Thus, TM mice provide a novel spontaneous model ofthan by Prkdc deficiency, suggesting that an alternative repair
CNS leukemia, a frequent and morbid complication of humanpathway can function in the absence of Prkdc (Bogue et al.,
lymphoblastic malignancies. Survival rates for children afflicted1998; Ferguson and Alt, 2001). This putative alternative repair
with acute lymphoblastic leukemia (ALL) have improved dramat-pathway could affect RAG-1/2-independent aspects of leuke-
ically, but remain poor for adult ALL (Cortes and Kantarjian,mogenesis in least two ways. First, it could actually enhance
1995; Ferrando and Look, 2000; Pui, 2000). Treatment failuregenomic instability in p53/Prkdc-deficient pro-B cells relative
to those from p53/KU80- or p53/XRCC4-deficient mice by pro- for ALL and non-Hodgkin’s lymphoma is frequently due to dis-
moting translocations through misrepair of RAG-1/2-indepen- semination of leukemic cells to the CNS (Berg et al., 2000;
dent DSB. Supporting this possibility is our observation that 6/7 Sandlund et al., 2000). Intrathecal chemotherapy and cranial
DM leukemias had at least 1 other clonal translocation besides irradiation prevent CNS relapse in most patients, but they are
the t(12;15) (Table 1), whereas such additional translocations associated with significant morbidity, such as cognitive delay,
were rare in p53/KU80-deficient pro-B cell leukemias (Difilip- endocrine failure, and a 2% 15-year risk of treatment-related
pantonio et al., 2000). Moreover, the extensive clonal instability brain tumors (Pui and Evans, 1998; Walter et al., 1998; Pui,
of IgH/c-Myc translocations and IgH we observed in DM leuke- 2000). Currently, cytogenetic markers are used to stratify pro/
mias was not noted in leukemias from p53//KU80/ or pre-B ALL patients, so that the most aggressive treatments are
p53//XRCC4/ mice. Thus, it appears that loss of p53 and
reserved for those with the highest risk of relapse (Ferrando
Prkdc imparts a greater degree of genomic instability than loss
and Look, 2000). Unfortunately, up to 40% of pediatric ALLof p53 and KU80 or XRCC4. Second, loss of XRCC4/LIG4 or
patients require CNS prophylaxis (Silverman et al., 2000). TheKU70/KU80, but not Prkdc, severely compromises cell growth
differential and highly reproducible incidence of CNS leukemia(Difilippantonio et al., 2000; Frank et al., 2000; Gao et al., 2000).
in DM versus TM mice will provide a valuable model system forTherefore, p53/XRCC4-deficient pro-B cells may stringently de-
elucidating the molecular pathways that control leptomeningealpend on RAG-1/2-dependent IgH translocations to induce over-
dissemination of leukemic lymphoblasts. This information mayexpression of c-Myc, allowing them to survive and proliferate
allow redefinition of risk factors for CNS relapse based on thewhen repair and cell growth are both severely compromised.
molecular characteristics of leukemic cells, ultimately providingIn contrast, alternative repair pathways in p53/Prkdc-deficient
novel therapeutic targets, as well as a more extensive panel ofpro-B cells may facilitate their survival and neoplastic transfor-
markers to more accurately identify patients with the highestmation by IgH/c-Myc-independent mechanisms. Consistent
with this notion, we found that TM leukemias overexpress c-Myc risk of CNS relapse.
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Experimental procedures Fluorescence in situ hybridization
Metaphase preparations from DM leukemias 544, 584, 596, 599, and 601
were analyzed by standard two-color FISH methods (Dracopoli, 2000). BACMice
All mice were bred and housed in specific pathogen-free conditions at the clones containing the TCR constant region (MBAC 77) or the most 5 V
gene cluster (MBAC01, Genbank accession AF259071) were kindly providedHospital for Sick Children animal facility. p53/Prkdcscid/scid (DM) mice and
their p53/Prkdcscid/scid littermates were bred from p53/ 129/Sv and by Dr. I. Lee, University of Washington (Seattle, WA). These two probes
were used to show that the breakpoints on the der(14) chromosome inPrkdcscid/scid ICR parental strains as previously described (Guidos et al., 1996).
The generation of RAG-2/Prkdcscid/scid mice from RAG-2/ (129/Sv and TM leukemia 485 did not disrupt the TCR	 locus. BAC clones containing
sequences from IgC2b to the JH cluster (MBAC 20B20) and c-Myc (MBACC57BL/6) and Prkdcscid/scid (C.B-17) mice has also been described (Guidos
et al., 1996). RAG-2/p53/Prkdcscid/scid (TM) mice were created by inter- 270G24) were obtained by screening a mouse BAC library (RPCI-22; http://
www.chori.org/bacpac) with IgC and c-Myc cDNA probes, respectively.breeding p53/Prkdcscid/scid mice and RAG-2/Prkdcscid/scid mice to generate
BAC clones containing sequences 3 of the IgC gene cluster (from Crip toRAG-2/p53/Prkdcscid/scid progeny. The latter mice were then intercrossed
IgC, CT7-199M11) or the most distal VH gene cluster (CT7-224M14) wereto produce Prkdcscid/scid mice segregating wild-type and mutant alleles of p53
provided by Dr. Roy Riblet (San Diego, CA). For use as FISH probes, BACand RAG-2. Two strategies were then used to produce a higher frequency
DNA was labeled by nick translation, either with biotin-14-dATP (GibcoBRL,of TM and RAG-2/ segregants: (1) RAG-2/p53/Prkdcscid/scid parents
Gaithersburg, MD) or digoxigenin-11-dUTP (Boehringer Mannheim). Thewere intercrossed, or (2) RAG-2/p53/Prkdcscid/scid male and RAG-
probes were then denatured for 10 min at 75C, preannealed at 37C for2/p53/Prkdcscid/scid females were mated. PCR amplification of tail DNA
1 hr, and hybridized to denatured slides overnight at 37C. Probes werewas used to genotype alleles at the p53 and RAG-2 loci (Guidos et al., 1996;
detected by using rhodamine-conjugated anti-digoxigenin antibody (Boeh-Williams et al., 2001). Adoptive transfer of TM and DM leukemic pro-B cells
ringer Mannheim) and FITC-avidin (Ventana, Tucson, AZ) antibodies. Chro-from lymph node, spleen, or thymus was performed by intravenous injection
mosomes were counterstained with DAPI. Sequential SKY and FISH wasof 107 cells in 200 l of PBS into sublethally irradiated (500 cGy) C57BL/6
performed as described to identify chromosomes containing IgH/c-Myc fu-RAG-2/ hosts, 6–8 weeks of age. Recipients were monitored daily for CNS
sions (Bayani et al., 2000).signs and/or for peripheral lymphadenopathy. At the first sign of morbidity,
animals were sacrificed and their brains processed for histological assess-
Northern and Southern blottingment of CNS leukemia. In addition, lymphoid tissues were analyzed by flow
DNA was prepared from infiltrated thymus or lymph nodes of TM and DMcytometry for the presence of leukemic pro-B cell lymphoblasts.
mice with disseminated pro-B cell leukemia, tail clips DNA of wild-type mice,
and a DM leukemic cell line (SC53.3) (Guidos et al., 1996). DNA samples wereFlow cytometry
digested with EcoRI and electrophoresed on 0.8% agarose gels. SouthernFlow cytometric analyses of thymocytes, splenocytes, lymph node, and
(Guidos et al., 1996) and Northern (Groves et al., 1995) blot filters werebone marrow cells using antibodies specific for CD4, CD8, and B220 were
prepared as described and probed with the following 32P-dCTP labeledperformed as previously described (Danska et al., 1994; Guidos et al., 1996).
probes: c-Myc and N-Myc (Feder et al., 1990), IgC (Fox and Danska, 1997),In addition, biotinylated-CD19 (6D5) was purchased from Pharmingen (San
IgJH4 (Atkinson et al., 1991), 
-actin (Groves et al., 1995), or HPRT (GrovesDiego, CA). Streptavidin-phycoerytherin was purchased from Caltag (South
et al., 1995).San Francisco, CA) and used as a second stage reagent with biotinylated
primary antibodies.
Acknowledgments
Histology
We wish to thank Gisele Knowles and Sherry Zhao for flow cytometry, andMice were sacrificed using carbon dioxide inhalation. Brains and spines
Dr. Inyoul Lee (University of Washington, Seattle, WA) and Roy Riblet (Torreywere dissected and fixed in 37% formalin for 2 weeks. Brains were cut in
Pines Institute for Molecular Studies, San Diego, CA) for BAC clones. R.A.G.the coronal plane and subsequently embedded in paraffin. Spines were
received fellowships from the Canadian Institutes of Health Research anddecalcified in 50% formic acid/20% sodium citrate solution for several weeks
the National Cancer Institute of Canada. M.T. is a recipient of a Nationaland then cut in the axial plane and embedded in paraffin. 10 m paraffin-
Cancer Institute of Canada Fellowship. C.J.W. held a Hospital for Sick Chil-embedded tissue sections were mounted on glass slides and stained with
dren RESTRACOMP studentship award. C.G. and J.D. hold Scientist Awardshematoxylin and eosin using standard techniques. For immunohistochemis-
from the Canadian Institutes of Health Research and the National Cancertry, brain sections were deparaffinized in xylene, then rehydrated in a de-
Institute of Canada, respectively. J.D. is a Principal Investigator of the Cana-creasing ethanol series. Endogenous peroxidase activity was blocked by
dian Genetic Disease Network. The work was supported by grants from theincubation of slides in 3% hydrogen peroxide solution diluted in methanol.
National Cancer Institute of Canada (with funds from the Canadian CancerSlides were then incubated sequentially with blocking serum, anti-B220,
Society).biotinylated anti-rat IgG, and avidin-horseradish peroxidase. Blocking serum
and secondary reagents were prepared from a Vectastain Elite ABC Kit
(Vector Laboratories Inc., Burlingame, CA). Diaminobenzidine-nickel peroxi-
dase substrate solution was prepared according to manufacturer’s instruc-
Received: November 14, 2002tions (Vector Laboratories Inc.) and dripped onto the surface of slides. Slides
Revised: December 11, 2002were counterstained with hematoxylin and mounted in AquaPerm (Immunon
Shandon, Pittsburgh, PA). Images were obtained using a Leica microscope
Referencesand Adobe Photoshop 3.0.4 software.
Artandi, S.E., Chang, S., Lee, S.L., Alson, S., Gottlieb, G.J., Chin, L., andSpectral karyotyping
DePinho, R.A. (2000). Telomere dysfunction promotes non-reciprocal trans-Primary leukemic cells were cultured from lymphoid tissues of moribund
locations and epithelial cancers in mice. Nature 406, 641–645.DM or TM mice as described (Guidos et al., 1996) for 1–6 days prior to the
induction of metaphase arrest by treatment with colcemid for 2–4 hr (0.05 Atkinson, M.J., Michnick, D.A., Paige, C.J., and Wu, G.E. (1991). Ig gene
g/ml) (Dracopoli, 2000). Cells were exposed to 0.075 M KCl for 10 min at rearrangements on individual alleles of Abelson murine leukemia cell lines
room temperature, followed by three changes of methanol/acetic acid (3:1) from (C57BL/6 x BALB/c) F1 fetal livers. J. Immunol. 146, 2805–2812.
prior to making metaphase spreads. The SKYKIT probe cocktail (Applied
Bailey, S.M., Meyne, J., Chen, D.J., Kurimasa, A., Li, G.C., Lehnert, B.E.,Spectral Imaging; ASI, Carlsbad, CA) was hybridized to cytogenetic prepara-
and Goodwin, E.H. (1999). DNA double-strand break repair proteins aretions following the manufacturer’s instructions, and slides were then counter-
required to cap the ends of mammalian chromosomes. Proc. Natl. Acad.stained with DAPI (Vector, Burlingame, CA). Images were captured using an
Sci. USA 96, 14899–14904.
SD200 spectral bioimaging system (ASI Ltd., Migdal Haemek, Israel)
attached to a Zeiss Axioplan 2 microscope and analyzed with ASI Spectral Bassing, C.H., Swat, W., and Alt, F.W. (2002). The mechanism and regulation
of chromosomal V(D)J recombination. Cell 109 (Suppl), S45–55.Imaging software.
48 CANCER CELL : JANUARY 2003
A R T I C L E
Bayani, J., Pandita, A., and Squire, J.A. (2000). Sequential G-Banding, SKY mosomal and associated molecular abnormalities in acute lymphoblastic
and FISH provide a refined identification of translocation breakpoints and leukemia. Semin. Hematol. 37, 381–395.
complex chromosomal rearrangements. Tech. Tips Online 01864.
Fox, C.J., and Danska, J.S. (1997). Interleukin 4 expression at the onset of
Berg, S.L., Steuber, C.P., and Poplack, D.G. (2000). Clinical manifestations islet-inflammation predicts non-destructive insulitis in NOD mice. J. Immu-
of acute lymhoblastic leukemia. In Hematology Basic Principles and Practice, nol. 158, 2414–2424.
R. Hoffman, E.J. Benz Jr., S.J. Shattil, B. Furie, H.J. Cohen, L.E. Silberstein,
Frank, K.M., Sharpless, N.E., Gao, Y., Sekiguchi, J.M., Ferguson, D.O., Zhu,and P. McGlcave, eds. (Philadelphia, PA: Churchill Livingstone), pp. 1070–
C., Manis, J.P., Horner, J., DePinho, R.A., and Alt, F.W. (2000). DNA ligase1078.
IV deficiency in mice leads to defective neurogenesis and embryonic lethality
Bogue, M.A., Jhappan, C., and Roth, D.B. (1998). Analysis of variable (diver- via the p53 pathway. Mol. Cell 5, 993–1002.
sity) joining recombination in DNA-dependent protein kinase (DNA-PK)-
Fugmann, S.D., Lee, A.I., Shockett, P.E., Villey, I.J., and Schatz, D.G. (2000).deficient mice reveals DNA-PK-independent pathways for both signal and
The RAG proteins and V(D)J recombination: complexes, ends, and transposi-coding joint formation. Proc. Natl. Acad. Sci. USA 95, 15559–15564.
tion. Annu. Rev. Immunol. 18, 495–527.
Chin, L., Artandi, S.E., Shen, Q., Tam, A., Lee, S.L., Gottlieb, G.J., Greider,
Gao, Y., Ferguson, D.O., Xie, W., Manis, J.P., Sekiguchi, J., Frank, K.M.,C.W., and DePinho, R.A. (1999). p53 deficiency rescues the adverse effects
Chaudhuri, J., Horner, J., DePinho, R.A., and Alt, F.W. (2000). Interplay ofof telomere loss and cooperates with telomere dysfunction to accelerate
p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability andcarcinogenesis. Cell 97, 527–538.
development. Nature 404, 897–900.
Chiu, P.P., Ivakine, E., Mortin-Toth, S., and Danska, J.S. (2002). Susceptibility
Gilley, D., Tanaka, H., Hande, M.P., Kurimasa, A., Li, G.C., Oshimura, M.,to lymphoid neoplasia in immunodeficient strains of nonobese diabetic mice.
and Chen, D.J. (2001). DNA-PKcs is critical for telomere capping. Proc. Natl.Cancer Res. 62, 5828–5834.
Acad. Sci. USA 98, 15084–15088.
Coquelle, A., Pipiras, E., Toledo, F., Buttin, G., and Debatisse, M. (1997).
Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N.,Expression of fragile sites triggers intrachromosomal mammalian gene am-
and Sawyers, C.L. (2001). Clinical resistance to STI-571 cancer therapyplification and sets boundaries to early amplicons. Cell 89, 215–225.
caused by BCR-ABL gene mutation or amplification. Science 293, 876–880.
Cortes, J.E., and Kantarjian, H.M. (1995). Acute lymphoblastic leukemia. A
comprehensive review with emphasis on biology and therapy. Cancer 76, Goytisolo, F.A., Samper, E., Edmonson, S., Taccioli, G.E., and Blasco, M.A.
2393–2417. (2001). The absence of the DNA-dependent protein kinase catalytic subunit
in mice results in anaphase bridges and in increased telomeric fusions with
Custer, R.P., Bosma, G.C., and Bosma, M.J. (1985). Severe combined immu- normal telomere length and G-strand overhang. Mol. Cell. Biol. 21, 3642–
nodeficiency (scid) in the mouse. Am. J. Path 120, 464–477. 3651.
D’Eustachio, P., and Riblet, R. (1999). Mouse chromosome 12. Mamm.
Groves, T., Katis, P., Madden, Z., Manickam, K., Ramsden, D., Wu, G.E.,
Genome 10, 953.
and Guidos, C.J. (1995). In vitro maturation of clonal CD4CD8 cell lines
in response to TCR engagement. J. Immunol. 154, 5011–5022.Danska, J.S., Pflumio, F., Williams, C., Huner, O., Dick, J.E., and Guidos,
C.J. (1994). Rescue of T cell-specific V(D)J recombination in SCID mice by
Guidos, C.J., Williams, C.J., Grandal, I., Knowles, G., Huang, M., and Danska,DNA-damaging agents. Science 266, 450–455.
J.S. (1996). V(D)J recombination activates a p53-dependent DNA damage
checkpoint in scid lymphoycte precursors. Genes Dev. 10, 2038–2054.Difilippantonio, M.J., Zhu, J., Chen, H.T., Meffre, E., Nussenzweig, M.C.,
Max, E.E., Ried, T., and Nussenzweig, A. (2000). DNA repair protein Ku80
Hellman, A., Zlotorynski, E., Scherer, S.W., Cheung, J., Vincent, J.B., Smith,suppresses chromosomal aberrations and malignant transformation. Nature
D.I., Trakhtenbrot, L., and Kerem, B. (2002). A role for common fragile site404, 510–514.
induction in amplification of human oncogenes. Cancer Cell 1, 89–97.
Difilippantonio, M.J., Petersen, S., Chen, H.T., Johnson, R., Jasin, M., Ka-
Karanjawala, Z.E., Grawunder, U., Hsieh, C.L., and Lieber, M.R. (1999). Thenaar, R., Ried, T., and Nussenzweig, A. (2002). Evidence for replicative repair
nonhomologous DNA end joining pathway is important for chromosomeof DNA double-strand breaks leading to oncogenic translocation and gene
stability in primary fibroblasts. Curr. Biol. 9, 1501–1504.amplification. J. Exp. Med. 196, 469–480.
Krug, U., Ganser, A., and Koeffler, H.P. (2002). Tumor suppressor genes inDracopoli, N.C. (2000). Current Protocols in Hum. Genet. (New York: John
normal and malignant hematopoiesis. Oncogene 21, 3475–3495.Wiley & Sons, Inc.).
Kuppers, R., and Dalla-Favera, R. (2001). Mechanisms of chromosomalEischen, C.M., Weber, J.D., Roussel, M.F., Sherr, C.J., and Cleveland, J.L.
translocations in B cell lymphomas. Oncogene 20, 5580–5594.(1999). Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-
induced lymphomagenesis. Genes Dev. 13, 2658–2669.
Lengauer, C., Kinzler, K.W., and Vogelstein, B. (1998). Genetic instabilities
in human cancers. Nature 396, 643–649.Faderl, S., Kantarjian, H.M., Talpaz, M., and Estrov, Z. (1998). Clinical signifi-
cance of cytogenetic abnormalities in adult acute lymphoblastic leukemia.
Lim, D.S., Vogel, H., Willerford, D.M., Sands, A.T., Platt, K.A., and Hasty, P.Blood 91, 3995–4019.
(2000). Analysis of ku80-mutant mice and cells with deficient levels of p53.
Mol. Cell. Biol. 20, 3772–3780.Feder, J.N., Guidos, C.J., Kusler, B., Carswell, C., Lewis, D., and Schimke,
R.T. (1990). A cell cycle analysis of growth-related genes expressed during
Livingstone, L.R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty,T lymphocyte maturation. J. Cell Biol. 111, 2693–2701.
T.D. (1992). Altered cell cycle arrest and gene amplification potential accom-
Felix, C.A., Megonigal, M.D., Chervinsky, D.S., Leonard, D.G., Tsuchida, N., pany loss of wild-type p53. Cell 70, 923–935.
Kakati, S., Block, A.M., Fisher, J., Grossi, M., Salhany, K.I., et al. (1998).
Look, A.T. (1997). Oncogenic transcription factors in the human acute leuke-Association of germline p53 mutation with MLL segmental jumping translo-
mias. Science 278, 1059–1064.cation in treatment-related leukemia. Blood 91, 4451–4456.
Malynn, B.A., de Alboran, I.M., O’Hagan, R.C., Bronson, R., Davidson, L.,Ferguson, D.O., and Alt, F.W. (2001). DNA double strand break repair and
DePinho, R.A., and Alt, F.W. (2000). N-myc can functionally replace c-mycchromosomal translocation: lessons from animal models. Oncogene 20,
in murine development, cellular growth, and differentiation. Genes Dev. 14,5572–5579.
1390–1399.
Ferguson, D.O., Sekiguchi, J.M., Chang, S., Frank, K.M., Gao, Y., DePinho,
Marx, J. (2002). Debate surges over the origins of genomic defects in cancer.R.A., and Alt, F.W. (2000). The nonhomologous end-joining pathway of DNA
Science 297, 544–546.repair is required for genomic stability and the suppression of translocations.
Proc. Natl. Acad. Sci. USA 97, 6630–6633.
Maser, R.S., and DePinho, R.A. (2002). Connecting chromosomes, crisis, and
cancer. Science 297, 565–569.Ferrando, A.A., and Look, A.T. (2000). Clinical implications of recurring chro-
CANCER CELL : JANUARY 2003 49
A R T I C L E
Mitelman, F., Mertens, F., and Johansson, B. (1997). A breakpoint map of involvement in children with newly diagnosed non-Hodgkin’s lymphoma. J.
Clin. Oncol. 18, 3018–3024.recurrent chromosomal rearrangements in human neoplasia. Nat. Genet. 15,
417–474.
Schimke, R.T., Kaufman, R.J., Alt, F.W., and Kellems, R.F. (1978). Gene amplifi-
cation and drug resistance in cultured murine cells. Science 202, 1051–1055.Morse, H.C., 3rd, Anver, M.R., Fredrickson, T.N., Haines, D.C., Harris, A.W.,
Harris, N.L., Jaffe, E.S., Kogan, S.C., MacLennan, I.C., Pattengale, P.K., and
Schmitt, C.A., McCurrach, M.E., de Stanchina, E., Wallace-Brodeur, R.R., andWard, J.M. (2002). Bethesda proposals for classification of lymphoid neoplasms
Lowe, S.W. (1999). INK4a/ARF mutations accelerate lymphomagenesis andin mice. Blood 100, 246–258.
promote chemoresistance by disabling p53. Genes Dev. 13, 2670–2677.
Muljo, S.A., and Schlissel, M.S. (2000). Pre-B and pre-T-cell receptors: conser-
Sharpless, N.E., Ferguson, D.O., O’Hagan, R.C., Castrillon, D.H., Lee, C., Farazi,vation of strategies in regulating early lymphocyte development. Immunol. Rev.
P.A., Alson, S., Fleming, J., Morton, C.C., Frank, K., et al. (2001). Impaired175, 80–93.
nonhomologous end-joining provokes soft tissue sarcomas harboring chromo-
somal translocations, amplifications, and deletions. Mol. Cell 8, 1187–1196.Nacht, M., Strasser, A., Chan, Y.R., Harris, A.W., Schlissel, M., Bronson, R.T.,
and Jacks, T. (1996). Mutations in the p53 and SCID genes cooperate in
Silverman, L.B., Sallan, S.E., and Cohen, H.J. (2000). Treatment of childhoodtumorigenesis. Genes Dev. 10, 2055–2066.
acute lymphoblastic leukemia. In Hematology Basic Principles and Practice,
R. Hoffman, E.J. Benz Jr., S.J. Shattil, B. Furie, H.J. Cohen, L.E. Silberstein,Padilla-Nash, H.M., Heselmeyer-Haddad, K., Wangsa, D., Zhang, H., Ghadimi,
B.M., Macville, M., Augustus, M., Schrock, E., Hilgenfeld, E., and Ried, T. (2001). and P. McGlcave, eds. (Philadelphia, PA: Churchill Livingstone), pp. 1078–1089.
Jumping translocations are common in solid tumor cell lines and result in
Tanaka, K., and Kamada, N. (1998). Segmental jumping translocation in leuke-recurrent fusions of whole chromosome arms. Genes Chromosomes Cancer
mia and lymphoma with a highly complex karyotype. Leuk. Lymphoma 29,30, 349–363.
563–575.
Paulson, T.G., Almasan, A., Brody, L.L., and Wahl, G.M. (1998). Gene amplifica-
Vaandrager, J.W., Schuuring, E., Philippo, K., and Kluin, P.M. (2000). V(D)Jtion in a p53-deficient cell line requires cell cycle progression under conditions
recombinase-mediated transposition of the BCL2 gene to the IGH locus inthat generate DNA breakage. Mol. Cell. Biol. 18, 3089–3100.
follicular lymphoma. Blood 96, 1947–1952.
Pipiras, E., Coquelle, A., Bieth, A., and Debatisse, M. (1998). Interstitial deletions
Vanasse, G.J., Concannon, P., and Willerford, D.M. (1999a). Regulated genomicand intrachromosomal amplification initiated from a double-strand break tar-
instability and neoplasia in the lymphoid lineage. Blood 94, 3997–4010.geted to a mammalian chromosome. EMBO J. 17, 325–333.
Vanasse, G.J., Halbrook, J., Thomas, S., Burgess, A., Hoekstra, M.F., Disteche,Price, R.A. (1979). Histopathology of CNS leukemia and complications of ther-
C.M., and Willerford, D.M. (1999b). Genetic pathway to recurrent chromosomeapy. Am. J. Pediatr. Hematol. Oncol. 1, 21–30.
translocations in murine lymphoma involves V(D)J recombinase. J. Clin. Invest.
103, 1669–1675.Prochazka, M., Gaskins, H.R., Shultz, L.D., and Leiter, E.H. (1992). The non-
obese diabetic scid mouse: model for spontaneous thymomagenesis associ-
Walter, A.W., Hancock, M.L., Pui, C.H., Hudson, M.M., Ochs, J.S., Rivera, G.K.,ated with immunodeficiency. Proc. Natl. Acad. Sci. USA 89, 3290–3294.
Pratt, C.B., Boyett, J.M., and Kun, L.E. (1998). Secondary brain tumors in
children treated for acute lymphoblastic leukemia at St Jude Children’s Re-Pui, C.H. (2000). Acute lymphoblastic leukemia in children. Curr. Opin. Oncol.
search Hospital. J. Clin. Oncol. 16, 3761–3767.12, 3–12.
Williams, C.J., Grandal, I., Vesprini, D.J., Wojtyra, U., Danska, J.S., and Guidos,Pui, C.H., and Evans, W.E. (1998). Acute lymphoblastic leukemia. N. Engl. J.
C.J. (2001). Irradiation promotes V(D)J joining and RAG-dependent neoplasticMed. 339, 605–615.
transformation in SCID T-cell precursors. Mol. Cell. Biol. 21, 400–413.
Richardson, C., and Jasin, M. (2000). Frequent chromosomal translocations
Windle, B., Draper, B.W., Yin, Y.X., O’Gorman, S., and Wahl, G.M. (1991). Ainduced by DNA double-strand breaks. Nature 405, 697–700.
central role for chromosome breakage in gene amplification, deletion formation,
Roth, D., Menetski, J., Nakajima, P., Bosma, M., and Gellert, M. (1992). V(D)J and amplicon integration. Genes Dev. 5, 160–174.
recombination: Broken DNA molecules with covalently sealed (hairpin) coding
Yin, Y., Tainsky, M.A., Bischoff, F.Z., Strong, L.C., and Wahl, G.M. (1992). Wild-ends in scid mouse thymocytes. Cell 70, 983–991.
type p53 restores cell cycle control and inhibits gene amplification in cells with
Rudolph, K.L., Millard, M., Bosenberg, M.W., and DePinho, R.A. (2001). Telo- mutant p53 alleles. Cell 70, 937–948.
mere dysfunction and evolution of intestinal carcinoma in mice and humans.
Zhu, C., Mills, K.D., Ferguson, D.O., Lee, C., Manis, J., Fleming, J., Gao, Y.,Nat. Genet. 28, 155–159.
Morton, C.C., and Alt, F.W. (2002). Unrepaired DNA breaks in p53-deficient
Sandlund, J.T., Murphy, S.B., Santana, V.M., Behm, F., Jones, D., Berard, cells lead to oncogenic gene amplification subsequent to translocations. Cell
109, 811–821.C.W., Furman, W.L., Ribeiro, R., Crist, W.M., Greenwald, C., et al. (2000). CNS
50 CANCER CELL : JANUARY 2003
